EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Safety of intravenous lacosamide in hospitalized children and neonates

Susan L Fong iD, Levon Utidjian, Moninder Kaur iD, Nicholas S Abend iD, Mark S Wainwright, Krista M Grande, Nadia Foskett, Robert Roebling, Réjean M Guerriero iD, Badal Jain, Suchitra Rao, Meredin Stoltenberg und 6 weitere

Epilepsia · 2023

DOI: 10.1111/epi.17676 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia, 2023. Verfasst von Susan L Fong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Child, Hospitalized. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of California Berkeley, Wolfson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Seizures are common in critically ill children and neonates, and these patients would benefit from intravenous (IV) antiseizure medications with few adverse effects. We aimed to assess the safety profile of IV lacosamide (LCM) among children and neonates.

Methods

This retrospective multicenter cohort study examined the safety of IV LCM use in 686 children and 28 neonates who received care between January 2009 and February 2020.

Results

Adverse events (AEs) were attributed to LCM in only 1.5% (10 of 686) of children, including rash ( n = 3, .4%), somnolence ( n = 2, .3%), and bradycardia, prolonged QT interval, pancreatitis, vomiting, and nystagmus ( n = 1, .1% each). There were no AEs attributed to LCM in the neonates. Across all 714 pediatric patients, treatment‐emergent AEs occurring in >1% of patients included rash, bradycardia, somnolence, tachycardia, vomiting, feeling agitated, cardiac arrest, tachyarrhythmia, low blood pressure, hypertension, decreased appetite, diarrhea, delirium, and gait disturbance. There were no reports of PR interval prolongation or severe cutaneous adverse reactions. When comparing children who received a recommended versus a higher than recommended initial dose of IV LCM, there was a twofold increase in the risk of rash in the higher dose cohort (adjusted incidence rate ratio = 2.11, 95% confidence interval = 1.02–4.38). Significance This large observational study provides novel evidence demonstrating the tolerability of IV LCM in children and neonates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsChild, HospitalizedInfant, NewbornHumansChildLacosamideCohort StudiesBradycardiaSleepinessAcetamidesTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

antiseizure medicationsepilepsyneonatalpediatric

Substanzen

LacosamideAnticonvulsantsAcetamides

Autor:innen und Institutionen

  • Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • UCB Pharma, Slough, UK.
  • Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Susan L Fong, Moninder Kaur, Nicholas S Abend, Réjean M Guerriero, Christopher B Forrest

Förderung

  • University of California Berkeley
  • Wolfson Foundation

Zitieren

APA

Fong, S. L., Utidjian, L., Kaur, M., Abend, N. S., Wainwright, M. S., Grande, K. M., Foskett, N., Roebling, R., Guerriero, R. M., Jain, B., Rao, S., Stoltenberg, M., Williams, P., Yuen, N., Dickinson, K., McDonald, J., Maltenfort, M., & Forrest, C. B. (2023). Safety of intravenous lacosamide in hospitalized children and neonates. Epilepsia. https://doi.org/10.1111/epi.17676

Vancouver

Fong SL, Utidjian L, Kaur M, Abend NS, Wainwright MS, Grande KM, et al. Safety of intravenous lacosamide in hospitalized children and neonates. Epilepsia. 2023. doi:10.1111/epi.17676

BibTeX
@article{Fong2023,
  author = {Fong, Susan L and Utidjian, Levon and Kaur, Moninder and Abend, Nicholas S and Wainwright, Mark S and Grande, Krista M and Foskett, Nadia and Roebling, Robert and Guerriero, Réjean M and Jain, Badal and Rao, Suchitra and Stoltenberg, Meredin and Williams, Paulette and Yuen, Nancy and Dickinson, Kimberley and McDonald, Jill and Maltenfort, Mitchell and Forrest, Christopher B},
  title = {Safety of intravenous lacosamide in hospitalized children and neonates},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17676}
}
Kostenlos starten →